E-viri
PDF
Recenzirano
Odprti dostop
-
Dummer, Reinhard; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Kirkwood, John M; Chiarion Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Lesimple, Thierry; Plummer, Ruth; Dasgupta, Kohinoor; Gasal, Eduard; Tan, Monique; Long, Georgina V; Schadendorf, Dirk
The New England journal of medicine, 09/2020, Letnik: 383, Številka: 12Journal Article
At 5 years of follow-up, the 12-month use of adjuvant therapy with dabrafenib (a BRAF inhibitor) plus trametinib (a MEK inhibitor) in patients with stage III melanoma with BRAF V600 mutations resulted in relapse-free survival of 52%, as compared with 36% with placebo.
